Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Moleculin Biotech's operating assets for the quarter that ended in Mar. 2026 was $13.05 Mil. Moleculin Biotech's operating liabilities for the quarter that ended in Mar. 2026 was $7.85 Mil. Moleculin Biotech's Total Assets for the quarter that ended in Dec. 2025 was $22.13 Mil. Therefore, Moleculin Biotech's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.23.
Moleculin Biotech Scaled Net Operating Assets Related Terms
Moleculin Biotech Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Moleculin Biotech's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moleculin Biotech Scaled Net Operating Assets Chart
MBRX vs ICU, LEXX, INTI: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Moleculin Biotech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moleculin Biotech Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moleculin Biotech's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Moleculin Biotech's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.23 mean?
Moleculin Biotech (MBRX) has a Scaled Net Operating Assets of 0.23 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Moleculin Biotech and its competitors.
Is Moleculin Biotech's Scaled Net Operating Assets too high?
Moleculin Biotech's current Scaled Net Operating Assets is 0.23. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Scaled Net Operating Assets compare to ICU and LEXX?
Moleculin Biotech's Scaled Net Operating Assets of 0.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current Scaled Net Operating Assets is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current Scaled Net Operating Assets of 0.23. The current Scaled Net Operating Assets is 0.23. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Scaled Net Operating Assets is 0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score
Get the complete analysis for MBRX
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBRX has been successfully added to your 
